Remdesivir for Treatment of COVID-19 Requiring Oxygen Support: A Cross-Study Comparison From 2 Large, Open-Label Studies
- 26 June 2024
- journal article
- research article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 79 (5) , 1182-1189
Abstract
Background: Remdesivir, an RNA-polymerase prodrug inhibitor approved for treatment of coronavirus disease 2019 (COVID-19), shortens recovery time and improves clinical outcomes. This prespecified analysis compared remdesivir plus standard of care (SOC) with SOC alone in adults hospitalized with COVID-19 requiring oxygen support in the early stage of the pandemic. Methods: Data for 10-day remdesivir treatment plus SOC from the extension phase of an open-label study (NCT04292899) were compared with real-world, retrospective data on SOC alone (EUPAS34303). Both studies included patients aged ≥18 years hospitalized with severe acute respiratory syndrome coronavirus 2 up to 30 May 2020, with oxygen saturation ≤94% on room air or supplemental oxygen (all forms), and with pulmonary infiltrates. Propensity score weighting was used to balance patient demographics and clinical characteristics across treatment groups. The primary endpoint was time to all-cause mortality or end of study (day 28). Time to discharge, with a 10-day landmark to account for duration of remdesivir treatment, was a secondary endpoint. Results: A total of 1974 patients treated with remdesivir plus SOC, and 1426 with SOC alone, were included after weighting. Remdesivir significantly reduced mortality versus SOC (hazard ratio [HR], 0.46; 95% confidence interval, .39–.54). This association was observed at each oxygen support level, with the lowest HR for patients on low-flow oxygen. Remdesivir significantly increased the likelihood of discharge at day 28 versus SOC in the 10-day landmark analysis (HR, 1.64; 95% confidence interval: 1.43–1.87). Conclusions: Remdesivir plus early-2020 SOC was associated with a 54% lower mortality risk and shorter hospital stays compared with SOC alone in patients hospitalized with COVID-19 requiring oxygen support. Clinical Trials Registration. ClinicalTrials.gov NCT04292899 and EUPAS34303.Keywords
Funding Information
- Gilead Sciences, Inc.
This publication has 38 references indexed in Scilit:
- Association of Remdesivir Treatment With Mortality Among Hospitalized Adults With COVID-19 in the United StatesJAMA Network Open, 2022
- RWD31 Comparison of Remdesivir As Monotherapy or in Combination with Steroids in Treating COVID-19 PatientsValue in Health, 2022
- SA5 The Effectiveness and Safety of Remdesivir for COVID-19: A Quantitative Meta-AnalysisValue in Health, 2022
- Remdesivir for the treatment of COVID-19: a systematic review and meta-analysisClinical Microbiology and Infection, 2022
- Remdesivir and three other drugs for hospitalised patients with COVID-19: final results of the WHO Solidarity randomised trial and updated meta-analysesThe Lancet, 2022
- Efficacy and safety of remdesivir in hospitalised COVID-19 patients: a systematic review and meta-analysisInfection, 2021
- Association of Remdesivir Treatment With Survival and Length of Hospital Stay Among US Veterans Hospitalized With COVID-19JAMA Network Open, 2021
- COVID-19: Understanding Inter-Individual Variability and Implications for Precision MedicineMayo Clinic Proceedings, 2021
- Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19JAMA, 2020
- Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trialThe Lancet, 2020